Intercell: Vaccine Development to Suspend

Businessn.a. ♦ Published: April 11, 2011; 12:19 ♦ (Vindobona)

Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710. The share of Intercell crashed seriously.

Intercell: Vaccine Development to Suspend / Picture: © Intercell

Merck, known as MSD outside the United States and Canada, and Intercell AG today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) recommended suspension of enrollment.

Although…